Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies

AIDS Research and Human Retroviruses

Volumn 20, Issue 11, 2004, Pages 1259-1268

  Young, Kelly R ^a   Teal, Benjamin E ^b   Brooks, Yvonne ^b   Green, Thomas D ^b   Bower, Joseph F ^a   Ross, Ted M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CODON; CONTROLLED STUDY; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; WILD TYPE;

AIDS VACCINES; ANIMALS; COMPLEMENT C3D; CROSS REACTIONS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MICE; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; VACCINATION; VACCINES, DNA;

EID: 9344247449     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2004.20.1259     Document Type: Article

References (72)

1. UNAIDS: www.unaids.org.
2. Katzenstein TL: Molecular biological assessment methods and understanding the course of the HIV infection. APMIS Suppl 2003; 114:1-37.
3. Pozniak A: Optimizing efficacy and tolerability in today's HAART. AIDS Read 2003;13:S4-8.
4. Rutherford G, Sangani P, and Kennedy G: Three- or four-versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst Rev 2003;4:CD002037.
5. Graham BS: NIH Vaccine Research Center Clinical Studies. http:// www.vrc.nih.gov/VRC/clinstudies.htm, 2001.
6. Mascola JR: Defining the protective antibody response for HIV-1. Curr Mol Med 2003;3:209-216.
7. Spearman P: HIV vaccine development: Lessons from the past and promise for the future. Curr HIV Res 2003;1:101-120.
8. Amara RR, Smith JM, Staprans SI, et al.: Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002;76:6138-6146.
9. D'Souza M, Durda P, Hanson C, et al.: Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: An international collaboration. AIDS 1991;5:1061-1070.
10. Vujcic L, Katzenstein D, Martin M, et al.: International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus. AIDS Res Hum Retroviruses 1990;6:847-853.
11. Vujcic LK and Quinnan GV Jr: Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res Hum Retroviruses 1995;11:783-787.
12. Quinnan GV Jr, Zhang PF, Fu DW, et al.: Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res Hum Retroviruses 1999;15:561-570.
13. Connor RI, Korber BT, Graham BS, et al.: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol 1998;72:1552-1576.
14. Zhang P, Bouma P, Park E, et al.: A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independence infectivity of human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 2002;76:644-655.
15. Dong M, Zhang PF, Grieder F, et al.: Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J. Virol 2003;77:3119-3130.
16. Donnelly JJ, Ulmer JB, and Liu MA: DNA vaccines. Dev Biol Strand 1998;95:43-53.
17. Liu MA, Fu TM, Donnelly JJ, et al.: DNA vaccines. Mechanisms for generation of immune responses. Adv Exp Med Biol 1998;42: 187-191.
18. Robinson HL: DNA vaccines for immunodeficency viruses. AIDS 1997;11(Suppl. A):S109-119.
19. Robinson HL: DNA vaccines: Basic mechanism and immune responses (Review). Int J Mol Med 1999;4:549-555.
20. Graham B: Clinical trials of HIV vaccines. Annu Rev Med 2002; 53:207-221.
21. Green TD, Newton BR, Rota PA, et al.: C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 2001;20: 242-248.
22. Lu S, Arthos J, Montefiori DC, et al.: Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996;70:3978-3991.
23. Robinson HL and Pertmer TM: DNA vaccines for viral infections: Basic studies and applications. Adv Virus Res 2000;55:1-74.
24. Bower JF, Yang X, Sodroski J, et al.: Elicitation of improved neutralizing antibodies using DNA vaccines expressing soluble stabilized HIV-1 envelope glycoprotein trimers conjugated to C3d. J Virol 2004;78:4710-4719.
25. Buchacher A, Predl R, Strutzenberger K, et al.: Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10: 359-369.
26. Green TD, Montefiori DC, and Ross TM: Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 2003;77:2046-2055.
27. Lu S, Santoro J, Fuller D, et al.: Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 1995;209:147-154.
28. Richmond JFL, Lu S, Santoro C, et al.: Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 1997;230:265-270.
29. Ross TM, Xu Y, Green TD, et al.: Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 2001;17:829-835.
30. Toapanta FR and Ross TM: Mouse strain-dependent differences in enhancement of immune responses by C3d. Vaccine 2004;22:1773-1781.
31. Letvin NL: Strategies for an HIV vaccine. J Clin Invest 2002; 110:15-20.
32. Dempsey PW, Allison MED, Akkaraju S, et al.: C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science 1996;271:348-350.
33. Mitchell JA, Green TD, Bright RA, et al.: Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 2003;21:902-914.
34. Ross TM, Xu Y, Bright RA, et al.: C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000;1:127-131.
35. Steward M, Cox V, Oldroyd R, et al.: Towards a human C3d-based vaccine for malaria. Mol Immunol 2001;38:118.
36. Haas KM, Hasegawa M, Steeber DA, et al.: Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 2002;17:713-723.
37. Test ST, Mitsuyoshi J, Connolly CC, et al.: Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun 2001;69:3031-3040.
38. Haas KM, Toapanta FR, Oliver JA, et al.: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol 2004;172:5833-5837.
39. Young KR, Smith JM, and Ross TM: Characterization of DNA vaccines expressing a non-infectious human immunodeficiency virus-like particle. Virology 2004;327:262-272.
40. Zhang PF, Chen X, Fu DW, et al.: Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection. J Virol 1999;73:5225-5230.
41. Posner MR: Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquired Immune Defic Syndr 1993;6:7-14.
42. Thali M: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. Virology 1993;67:3978-3988.
43. Thali M, Furman C, Helseth E, et al.: Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J Virol 1992;66:5516-5524.
44. Doranz BJ, Baik SS, and Doms RW: Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 1999;73:10346-10358.
45. Haynes JR, Fuller DH, Eisenbraun MD, et al.: Accell particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses. AIDS Res Hum Retroviruses 1994;10: S43-45.
46. Pertmer TM, Eisenbraun MD, McCabe D, et al.: Gene gun based nucleic acid immunization eliciting of humoral and cytotoxic T lymphocyte response following epidermal delivery of nanogram quantitation of DNA. Vaccine 1995;13:1427-1430.
47. Cole K, Rowles J, Jagerski B, et al.: Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol 1997; 71:5069-5079.
48. Hall JT and Heckel C: Thiocyanate elution estimation of relative antibody avidity. J Immunol Methods 1988;115:153-154.
49. Ito KY, Takeuchi Y, Ito K, et al.: S train-dependent antibody response induced by DNA immunization. Immunol Lett 2000;74:245-250.
50. Leung L, Srivastava IK, Kan E, et al.: Immunogenicity of HIV-1 Env and Gag baboons using a DNA prime/protein boost regimen. AIDS 2004;18:991-1001.
51. MacDonald RA, Hosking CS, and Jones CL: The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 1988;106:191-194.
52. Shiver JW, Davies ME, Yasutomi Y, et al.: Anti-HIV Env immunities elicited by nucleic acid vaccines. Vaccine 1997;15:884-887.
53. Park EJ, Vujcic LK, Anand R, et al.: Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 1998;72:7099-7107.
54. Quinnan GV Jr, Zhang PF, Fu DW, et al.: Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants. AIDS Res Hum Retroviruses 1998;14:939-949.
55. Park EJ, Gorny MK, Zolla-Pazner S, et al.: A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J Virol 2000;74:4183-4191.
56. Park EJ and Quinnan GV Jr: Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J Virol 1999;73:5707-5713.
57. Clapham P, McKnight A, and Weiss R: Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: Induction and enhancement by soluble CD4. J. Virol 1992;66:3531-3537.
58. Sullivan N, Sun Y, Satterntau Q, et al.: CD4-induced conformational changes in the HIV-1 gp120 glycoprotein: Consequences for virus entry and neutralization. J Virol 1998;72:4694-4703.
59. Watkins BA, Buge S, Aldrich K, et al.: Resistance of HIV-1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding or multiple sites. J Virol 1996;70:8431-8437.
60. Wyatt R, Kwong P, Desjardins E, et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-711.
61. Wyatt R, Sullivan N, Thali M, et al.: Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 1993;67:4557-4565.
62. Andre S, Seed B, Eberle J, et al.: Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol 1998;72:1497-1503.
63. Haas J, Park EC, and Seed B: Coden usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996;6:315-324.
64. Liu F, Mboudjeka I, Shen S, et al.: Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion. Vaccine 2004;22:1764-1772.
65. Ghiara JB, Ferguson DC, Satterthwait AC, et al.: Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site. J Mol Biol 1997;266:31-39.
66. Lu M and Kim PS: A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 1997;15: 46-71.
67. Kolchinsky P, Kiprilov E, and Sodroski J: Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001;75:2041-2050.
68. Puffer BA, Pohlmann S, Edinger AL, et al.: CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 2002;76:2595-2605.
69. Heyman B, Wiersma EJ, and Kinoshita T: In vivo inhibition of the antibody response to a complement receptor-specific monoclonal antibody. J Exp Med 1990;172:665-668.
70. Thyphronitis G, Kinoshita T, Inoue K, et al.: Modulation of mouse complement receptors 1 and 2 suppress antibody responses in vivo. J Immunol 1991;147:224-230.
71. Wiersma E, Kinoshita T, and Heyman B: Inhibition of immunological memory and T-independent humoral responses by monoclonal antibodies specific for murine complement receptors. Eur J Immunol 1991;21:2501-2506.
72. Chakravarty L, Zabel MD, Weis JJ, et al.: Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation. Int Immunol 2002;14:139-146.